Clinical Study

Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles

Andrew W. Gardner,1,2,3 Petar Alaupovic,4 Donald E. Parker,5 Polly S. Montgomery,1 Omar L. Esponda,6 and Ana I. Casanegra6

1 Reynolds Oklahoma Center on Aging, Donald W. Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK 73117, USA
2 Veterans Affairs Medical Center, Oklahoma City, OK 73104, USA
3 University of Oklahoma Health Sciences Center, O’Donoghue Research Building, II22 NE 13th Street, Suite 1200, Oklahoma City, OK 73117, USA
4 Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
5 Department of Biostatistics and Epidemiology, OUHSC, Oklahoma City, OK 73117, USA
6 Cardiovascular Section, Department of Medicine, OUHSC, Oklahoma City, OK 73117, USA

Correspondence should be addressed to Andrew W. Gardner; andrew-gardner@ouhsc.edu

Received 23 June 2013; Accepted 12 August 2013

Copyright © 2013 Andrew W. Gardner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n = 17) or untreated (n = 12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P < 0.05) and lower values of Lp-A-I:A-II (P < 0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P < 0.05), Lp-A-II:B:C:D:E (P < 0.05), Lp-B:E + Lp-B:C:E (P < 0.05), Lp-B:C (P < 0.05), and Lp-A-I (P < 0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.

1. Introduction

Peripheral artery disease (PAD) is a highly prevalent medical condition, [1] and it is associated with high prevalence of co-existing vascular diseases in the coronary, cerebral, and renal arteries [2, 3]. Consequently, PAD is a deadly [4, 5] and costly disease [6]. Many patients with PAD are physically limited by ambulatory leg pain [7, 8], resulting in baseline ambulatory and physical dysfunction [9, 10], low physical activity [11, 12], and poor health-related quality of life [13]. Although PAD is considered by many to be a benign disease, as 70 to 80% of patients have stable claudication that does not progress to worsening claudication or critical limb ischemia [2], PAD patients have increased rates of functional decline and mobility loss compared to those without PAD [14], leading to higher rates of hospitalization and loss of independence [15]. We have previously found that cardiovascular risk factors, such as dyslipidemia, are associated with impaired ambulation and vascular function in subjects with PAD and claudication [16, 17]. Dyslipidemia is typically evident by an elevation in low-density lipoprotein cholesterol (LDL-C). Recently, the multinational INTERHEART study showed
that apolipoprotein B (apoB) was a stronger predictor of myocardial infarction than LDL-C [18], and it is inversely related to physical activity [19] and modifiable with exercise training [20]. Thus, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication because dyslipidemia is prevalent in 85–90% of subjects [21], and physical activity levels are low [22].

The classification of plasma lipoproteins based on apolipoprotein composition instead of size and density provides a new way of characterizing plasma lipoproteins as these subclasses differ not only in their apolipoprotein composition but also in their metabolic properties [23, 24].

In subjects with severe PAD requiring revascularization, women with both localized aortic stenosis and diffuse segmental stenosis have impaired apolipoprotein profiles compared to controls [25], and men with aneurysmal and stenotic aortoiliac diseases have similar, abnormal profiles [26]. However, little is known about apolipoprotein measures in subjects with claudication.

Statin therapy improves claudication measures [27], suggesting that lowering lipids has a role in improving symptoms. However, it is not clear whether apolipoproteins are improved with statin medications in subjects with claudication. Therefore, the purposes of this study are (1) to compare plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) and claudication and in control subjects and (2) to compare the plasma apolipoprotein profiles of subjects with PAD either treated or untreated with statin medications. We hypothesized that subjects with PAD have impaired apolipoprotein profiles compared to controls and that those treated with statin medications have more favorable apolipoprotein profiles than untreated subjects.

2. Methods

2.1. Subjects

2.1.1. IRB Approval and Informed Consent. The procedures used in this study were approved by the Institutional Review Board at the University of Oklahoma Health Sciences Center and by the Research and Development Committee at the Oklahoma City VA Medical Center. Written informed consent was obtained from each patient prior to investigation.

2.1.2. Recruitment. Subjects participated in this study at the General Clinical Research Center, at the University of Oklahoma Health Sciences Center. Subjects with PAD and claudication were recruited by referrals from vascular and primary care clinics at the University of Oklahoma Health Sciences Center and the Oklahoma City VA Medical Center. Control subjects were recruited by newspaper advertisements for the assessment of cardiovascular risk factors in individuals without a history of cardiovascular diseases.

2.1.3. Screening of the Intermittent Claudication Group. Subjects with claudication secondary to vascular insufficiency were included in this study if they met the following criteria: (a) a history of ambulatory leg pain [28] and (b) an ankle-brachial index (ABI) ≤ 0.90 [2]. Subjects were excluded for the following conditions: (a) absence of PAD (ABI > 0.90 at rest), (b) inability to obtain an ABI measure due to non-compressible vessels, (c) use of cilostazol and pentoxifylline initiated within three months prior to investigation, (d) active cancer, (e) end stage renal disease defined as stage 5 chronic kidney disease, and (f) abnormal liver function.

2.1.4. Screening of the Control Group. Control subjects were included in this study if they met the following criteria: (a) no history of ambulatory leg pain [28] and (b) an ABI ≥ 1.00. Controls were excluded from this study for the following conditions: (a) an ABI < 1.00, (b) inability to obtain an ABI measure due to noncompressible vessels, (c) poorly controlled hypertension (resting systolic blood pressure > 200 mm Hg or resting diastolic blood pressure > 120 mm Hg), (d) history of cardiovascular disease, cerebrovascular disease, myocardial infarction, or peripheral revascularization, (f) active cancer, (g) end stage renal disease defined as stage 5 chronic kidney disease, and (h) abnormal liver function.

2.2. Measures

2.2.1. Plasma Apolipoproteins and Lipoprotein Lipids. Subjects arrived in the morning fasted but were permitted to take their usual morning medication regimen. Blood samples were drawn into chilled EDTA (1 mg/dL of blood) containing tubes after an overnight fast.

Blood was analyzed for fasting glucose concentrations as part of the automated chemistry battery (complete metabolic panel). Blood was also analyzed for fasting lipids, apoB, apolipoprotein C-III (apoC-III), and apolipoprotein subparticles consisting of Lp-B-II, Lp-A-II:B:C:D:E, Lp-B:E + Lp-B:C:E, Lp-B, Lp-B:C, Apo AI, Lp-A-I, and Lp-A-I:A-II. Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured by standardized enzymatic procedure [29, 30]. Very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) were estimated by Friedewald formula, and non-HDL-C was calculated as total cholesterol minus HDL-C. To put the apolipoprotein subparticles in better context, they can be compared to the density classes of lipoproteins. Densities of subparticles ranging solely in the atherogenic density classes of chylomicrons, VLDL-C, intermediate density lipoprotein cholesterol (ILDL-C), and LDL-C are Lp-B:E + Lp-B:C:E, Lp-B:C, and Lp-B-II. Densities of apolipoprotein subparticles in the density classes of VLDL, LDL, LDL, and HDL are Lp-A-II:B:C:D:E and Lp-B. Densities of subparticles in the density classes of LDL-C, HDL, HDL, and very high-density lipoprotein cholesterol (VHDL-C) are Lp-A-I and Lp-A-I:A-II. Finally, the density of the only apolipoprotein subparticle that ranges solely within the HDL density classes of HDL, HDL, and VHDL is ApoAI.

Blood was frozen at minus 70°C for subsequent analysis of apolipoprotein levels. ApoC-III was measured in the total plasma sample and in the heparin-manganese precipitate (HP), following reconstitution of the original volume. ApoC-III HP represents the apoC-III bound to apoB-containing lipoproteins. ApoC-III in the heparin-manganese supernate (HS) represents apoC-III bound to apoA-containing
3. Results

3.1. Clinical Characteristics. The clinical characteristics of the PAD groups and the control group are shown in Table 1. The groups were significantly different in age ($P = 0.003$), with the control group being the youngest. There was no group difference in the distribution of men and women ($P = 0.695$). Since the subjects in the healthy control group were required to be free of diabetes, hypertension, current smoking, and coronary artery disease, group comparisons on these variables were limited to the two PAD groups. In the PAD group taking statins, the percentage of subjects who had diabetes was higher than in the PAD group not taking statins ($P = 0.005$). The two PAD groups were not significantly different in the prevalence of hypertension ($P = 0.144$), current smoking ($P = 0.176$), and coronary artery disease ($P = 0.913$).

3.2. Lipid Measures. Lipid measures of subjects with PAD and controls are displayed in Table 2. Triglycerides ($P < 0.01$), LDL cholesterol ($P = 0.011$), HDL cholesterol ($P = 0.016$), and the triglyceride/HDL cholesterol ratio ($P = 0.005$) were significantly different among the groups. The age-adjusted mean values of triglycerides ($P < 0.01$) and the triglyceride/HDL cholesterol ratio ($P < 0.001$) were significantly higher in the PAD groups than in the control group, whereas the HDL cholesterol ($P < 0.05$) and the LDL cholesterol ($P < 0.01$) were significantly lower in the PAD groups. The only age-adjusted mean that was significantly different between the two PAD groups was the LDL cholesterol/HDL cholesterol ratio, as the subjects on statin therapy had a lower value ($P < 0.05$).

3.3. Apolipoprotein Measures. Apolipoprotein measures of subjects with PAD and controls are displayed in Table 3. Lp-B:C ($P = 0.013$) and Lp-A-I ($P = 0.049$) were significantly different among the groups. The age-adjusted mean value of Lp-B:C ($P < 0.05$) was significantly higher in the PAD groups than in the control group, whereas the Lp-B ($P < 0.05$) and Lp-A-I ($P < 0.05$) were significantly lower in the PAD groups. The age-adjusted mean values significantly different between the two PAD groups were ApoB ($P < 0.05$), Lp-A-I ($P < 0.05$), Lp-A-I:B:C:D:E ($P < 0.05$), Lp-B:E + Lp-B:C:E ($P < 0.05$), Lp-B:C ($P < 0.05$), and Lp-A-I ($P < 0.05$), as the subjects on statin therapy had lower values.

4. Discussion

4.1. Subjects with PAD Compared to Controls

4.1.1. Apolipoprotein Measures. To our knowledge, this is the first study to compare apolipoprotein subparticles in subjects with PAD and claudication compared to control subjects. The PAD groups had a 5 mg/dL higher age-adjusted Lp-B:C value than the control group, a 6 mg/dL lower age-adjusted Lp-B level, and a 9 mg/dL lower age-adjusted Lp-A-I ($P < 0.05$). The higher Lp-B:C particles level in the PAD group supports a previous study with type 2 diabetic patients that showed that levels of Lp-B:C particles were independently associated with macrovascular complications, as defined by the presence of coronary artery disease, PAD or cerebrovascular disease, or more than one of these [37]. The lower Lp-A-I:$P < 0.01$ particles level in the PAD group is supportive of other studies that found that these particles have some antiatherogenic potential, due to its role in reverse cholesterol transport as part of the HDL-C subpopulation. However, its true participation in the antiatherogenic or atherogenic process is still to be elucidated [24]. The impaired apolipoprotein subparticle measures of Lp-B:C and Lp-A-I:$P < 0.05$ II in the subjects with PAD also support previous work that subjects with more severe PAD requiring revascularization had impaired apolipoprotein profiles compared to controls [25]. An unexpected finding was that the PAD group as a whole had lower Lp-B particles level than the control group. This may be a reflection of the efficiency of the control group in lipolytic degradation as Lp-B is the main lipoprotein degradation product [38].

lipoproteins. The values for apoC-III HS were derived by subtracting apoC-III HP from total plasma apoC-III.

Density-defined lipoprotein classes, including total cholesterol, triglycerides, and HDL-C, were measured as previously described [31, 32]. VLDL-C and LDL-C were measured according to the Friedewald formula [30]. ApoA-I, ApoB, and ApoC-III were determined by the immunoturbidimetric procedure of Riepponen et al. [33] using corresponding monospecific polyclonal antisera generated in this laboratory. Apo-A-I:A-II lipoprotein subclasses were measured by the procedure of Marz et al. [34], ApoC-III was also measured in Apo-A-I-containing lipoproteins (ApoC-III HS) and in ApoB-containing lipoproteins (ApoC-III HP) [35]. ApoC-III bound to HS and HP was measured by electroimmunoassay [36]. The ratio of ApoC-III HS/ApoC-III HP is denoted as the ApoC-III ratio (ApoC-III R).

2.2.2. Medical History and Physical Examination. After the blood samples were drawn, subjects were seen by a study physician. Demographic information, height, weight, cardiovascular risk factors, comorbid conditions, claudication history, ABI, and a list of current medications were obtained from a medical history and physical examination.

2.3. Statistical Analyses. Within each of the three groups, controls, PAD subjects treated with statin, and PAD subjects not treated with statin, measurement variables were summarized as means and standard deviations. Dichotomous variables were summarized as percent with attribute present. As preliminary analysis, the mean ages of the three groups were compared using a one-way ANOVA and sex distributions compared using Chi-Square test in Tables 2 and 3. Dichotomous variables in PAD groups were compared using single degree of freedom Chi-Square test. In order to adjust for the observed age difference, lipid measures were compared among the three groups using a one-way ANCOVA with age as covariate followed by two orthogonal contrasts—control mean minus average of two PAD group means and PAD no statin group minus PAD subjects with statin. Apolipoprotein means were compared in a similar manner. Computations were made using NCSS statistical package with significance defined as $P < 0.05$. 

The prevalence of hypertension ($P = 0.005$) was higher than in the PAD group not taking statins ($P = 0.144$), current smoking ($P = 0.176$), and coronary artery disease ($P = 0.913$).
Table 1: Clinical characteristics of subjects with peripheral artery disease (PAD) and controls. Values are means (standard deviation) or percentage of subjects in each category.

| Variables                        | Control group (n = 39) | PAD no statin group (n = 12) | PAD statin group (n = 17) | P value |
|----------------------------------|------------------------|-----------------------------|---------------------------|---------|
| Age (years)                      | 55 (13)                | 66 (13)                     | 63 (11)                   | 0.003   |
| Sex (% men)                      | 54                     | 67                          | 53                        | 0.695   |
| Diabetes (% yes)                 | —                      | 0                           | 47                        | 0.005   |
| Hypertension (% yes)             | —                      | 92                          | 69                        | 0.144   |
| Current smoking (% yes)          | —                      | 67                          | 41                        | 0.176   |
| Coronary artery disease (% yes)  | —                      | 33                          | 35                        | 0.913   |

Table 2: Lipid measures of subjects with peripheral artery disease (PAD) and controls. Values are means (standard deviation).

| Variables                        | Control group (n = 39) | PAD no statin group (n = 12) | PAD statin group (n = 17) | ANCOVA P value | ΔAdjusted mean = control group − PAD groups | ΔAdjusted mean = PAD no statin group − PAD statin group |
|----------------------------------|------------------------|-----------------------------|---------------------------|----------------|---------------------------------------------|---------------------------------------------------|
| Triglycerides (mg/dL)            | 87.5 (41.9)            | 154.1 (116.9)               | 133.9 (92.3)              | 0.011          | −60.6**                                      | 21.6                                              |
| Total cholesterol (mg/dL)        | 181.5 (53.2)           | 177.8 (31.3)                | 157.1 (32.3)              | 0.062          | 23.4*                                        | 17.4                                              |
| HDL-C (mg/dL)                    | 52.4 (15.2)            | 44.3 (13.6)                 | 46.8 (13.7)               | 0.016          | 10.7*                                        | −3.9                                              |
| LDL-C (mg/dL)                    | 117.5 (38.6)           | 108.3 (28.0)                | 87.2 (26.6)               | 0.011          | 23.5**                                       | 20.2                                              |
| LDL-C/HDL-C                      | 2.35 (0.83)            | 2.65 (1.22)                 | 1.92 (0.64)               | 0.078          | −0.1                                         | 0.77                                               |
| Non-HDL-C (mg/dL)                | 129.1 (47.8)           | 133.5 (32.9)                | 110.3 (27.9)              | 0.158          | 12.6                                         | 21.3                                              |
| Total cholesterol/HDL-C ratio    | 3.62 (1.10)            | 4.36 (1.60)                 | 3.56 (1.04)               | 0.076          | −0.5                                         | 0.86                                               |
| Triglyceride/HDL-C ratio         | 1.93 (1.48)            | 4.19 (3.78)                 | 3.50 (3.35)               | 0.005          | −2.3***                                       | 0.82                                               |

*P < 0.05, **P < 0.01, and ***P < 0.001.
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

Table 3: Apolipoprotein measures of subjects with peripheral artery disease (PAD) and controls. Values are means (standard deviation).

| Variables                        | Control group (n = 39) | PAD no statin group (n = 12) | PAD statin group (n = 17) | ANCOVA P value | ΔAdjusted mean = control group − PAD groups | ΔAdjusted mean = PAD no statin group − PAD statin group |
|----------------------------------|------------------------|-----------------------------|---------------------------|----------------|---------------------------------------------|---------------------------------------------------|
| ApoB (mg/dL)                     | 90.9 (12.3)            | 93.8 (16.1)                 | 82.1 (19.2)               | 0.085          | 1.7                                         | 12.0                                              |
| ApoC-III (mg/dL)                 | 10.1 (3.0)             | 10.1 (2.1)                  | 10.0 (3.4)                | 0.890          | 0.4                                         | 0.0                                               |
| ApoC-III HS (mg/dL)              | 6.6 (2.7)              | 6.9 (1.3)                   | 6.5 (2.0)                 | 0.507          | 0.6                                         | 0.2                                               |
| ApoC-III HP (mg/dL)              | 3.4 (1.3)              | 3.1 (0.9)                   | 3.5 (3.0)                 | 0.823          | −0.2                                        | −0.3                                              |
| ApoC-III ratio                   | 2.26 (1.32)            | 2.37 (0.63)                 | 2.64 (1.46)               | 0.552          | 0.19                                        | −0.42                                             |
| Lp-B-II (mg/dL)                  | 90.4 (13.2)            | 83.6 (17.9)                 | 81.5 (18.9)               | 0.213          | 6.9                                         | 2.4                                               |
| Lp-A-II:B:C:D:E (mg/dL)          | 12.1 (5.8)             | 23.0 (33.4)                 | 10.0 (4.7)                | 0.079047       | −3.0                                        | 12.5*                                              |
| Lp-B:E + Lp-B:C:E (mg/dL)        | 12.4 (4.5)             | 22.6 (26.4)                 | 12.7 (5.6)                | 0.066          | −4.2                                        | 9.5*                                               |
| Lp-B (mg/dL)                     | 59.8 (7.2)             | 50.6 (20.0)                 | 54.8 (12.1)               | 0.127          | 6.1*                                        | −3.8                                              |
| Lp-B:C (mg/dL)                   | 9.5 (4.0)              | 20.0 (21.1)                 | 10.4 (4.8)                | 0.013          | −5.1*                                       | 9.4*                                               |
| Apo A1 (mg/dL)                   | 132.5 (16.5)           | 134.8 (20.2)                | 124.7 (18.9)              | 0.156          | 5.4                                         | 9.2                                               |
| Lp-A-I (mg/dL)                   | 34.8 (4.4)             | 48.2 (37.9)                 | 32.5 (6.0)                | 0.049          | −3.6                                        | 15.1*                                              |
| Lp-A-I:A-II (mg/dL)              | 977.1 (12.9)           | 870.0 (27.2)                | 921.5 (15.5)              | 0.134          | 8.8*                                        | −5.3                                              |
| B/A1 ratio                       | 0.69 (0.14)            | 0.62 (0.13)                 | 0.66 (0.17)               | 0.673          | 0.03                                        | −0.03                                             |
| Lp-B/C-III HP ratio              | 20.15 (8.46)           | 18.33 (8.88)                | 21.36 (9.34)              | 0.461          | 1.78                                        | −3.54                                              |

*P < 0.05.
4.1.2. Lipid Measures. The PAD groups had a 60 mg/dL higher age-adjusted triglyceride level than the control group, a 2.3 higher age-adjusted ratio of triglyceride/HDL-C, an 11 mg/dL lower age-adjusted HDL-C concentration, and a 23 mg/dL lower age-adjusted LDL-C value.

The higher triglyceride level in the PAD group supports a previous observation of a 118% higher triglyceride concentration in subjects with diffuse, stenotic PAD compared to controls [25]. The impairments in triglycerides and HDL-C are both factors that cluster together and are components of metabolic syndrome [39]. We have previously found that metabolic syndrome is associated with worse claudication, physical function, health-related quality of life, and peripheral circulation in subjects with PAD [40] and that these factors are progressively impaired as the number of metabolic syndrome components increases. We have also found that dyslipidemia is associated with impaired calf muscle hemoglobin oxygen saturation during ambulation [16], which suggests that dyslipidemia impairs the microcirculation and may be a physiologic mechanism for worse ambulatory function.

Surprisingly, the PAD group had lower LDL-C than the controls, possibly because 17 of 29 subjects with PAD were taking statin medications. Since apoB was not different between the PAD and control groups, this suggests that subjects with PAD may have had higher values of intermediate-density lipoprotein cholesterol (IDL-C) and very low-density lipoprotein cholesterol (VLDL-C) because apoB directly measures the total number of atherogenic particles [41]. Thus, higher IDL-C and VLDL-C values would counteract lower LDL-C, resulting in similar apoB levels.

4.2. Statin Therapy in Subjects with PAD. To our knowledge, this is the first study to examine the relationship between statin therapy and apolipoprotein subparticles in subjects with PAD and claudication. Subjects with PAD who were taking statin medications had lower values of LDL-C/HDL-C ratio, apoB, Lp-A-II:B:C:D:E, Lp-B:E + Lp-B:C:E, Lp-B:C, and Lp-A-I than subjects who were not taking statin medications. These findings agree with the observation that subjects with PAD who take statin medications have lower LDL-C [42] than those not on statins and that LDL-C is reduced with statin therapy [43]. Furthermore, our finding of a lower apoB level in subjects with PAD taking statin medications compared to those not taking statin medications suggests that they also had a lower number of atherogenic particles because there is only one apoB molecule on the surface of all LDL-C, IDL-C, and VLDL-C [41]. Our findings suggest that statin medications reduce the number of atherogenic particles in subjects with PAD, which may improve survival [42], event-free survival [42], and microcirculation during exercise [16].

The effects of statins among apolipoproteins subparticles are not uniform and depend on both the type of pharmacological agent and the type of apolipoprotein subparticle being measured [24]. For example, although atorvastatin and simvastatin have similar profiles in the reduction of LDL-C, atorvastatin is better at reducing levels of Lp-B:C when compared to simvastatin [44]. However simvastatin is superior to atorvastatin in its capacity to lower levels of LDL-C, atorvastatin is better at reducing levels of Lp-B:C and simvastatin have similar profiles in the reduction of LDL-C, atorvastatin is better at reducing levels of Lp-B:C and simvastatin have similar profiles in the reduction of LDL-C, atorvastatin is better at reducing levels of Lp-B:C and simvastatin have similar profiles in the reduction of LDL-C, atorvastatin is better at reducing levels of Lp-B:C and simvastatin have similar profiles in the reduction of LDL-C.
but will need the rigor of a formal randomized control trial. Until then, these results are worth reporting as observed findings in the first study to compare apolipoprotein subparticles in subjects with PAD and claudication compared to control subjects.

Acknowledgments
Grant support is provided by the National Institute on Aging (R01-AG-24296), Oklahoma Center for the Advancement of Science and Technology (HR09-035), and General Clinical Research Center (M01-RR-14467).

References
[1] V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Executive summary: heart disease and stroke statistics—2012 update: a report from the American heart association,” *Circulation*, vol. 125, no. 1, pp. 188–197, 2012.
[2] A. T. Hirsch, Z. J. Haskal, N. R. Hertzler et al., “ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease); endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation,” *Circulation*, vol. 113, no. 11, pp. e463–e654, 2006.
[3] L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, and F. G. R. Fowkes, “Inter-society consensus for the management of peripheral arterial disease (TASC II),” *Journal of Vascular Surgery*, vol. 45, no. 1, pp. S5–S67, 2007.
[4] E. P. Brass and W. R. Hiatt, “Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies,” *Vascular Medicine*, vol. 11, no. 3, pp. 141–145, 2006.
[5] M. H. Criqui, R. D. Langer, A. Froncek et al., “Mortality over a period of 10 years in patients with peripheral arterial disease,” *The New England Journal of Medicine*, vol. 326, no. 6, pp. 381–386, 1992.
[6] A. T. Hirsch, L. Hartman, R. J. Town, and B. A. Virnig, “National health care costs of peripheral arterial disease in the Medicare population,” *Vascular Medicine*, vol. 13, no. 3, pp. 209–215, 2008.
[7] A. W. Gardner, J. S. Skinner, B. W. Cantwell, and L. K. Smith, “Progressive vs single-stage treadmill tests for evaluation of claudication,” Medicine & Science in Sports & Exercise, vol. 23, no. 4, pp. 402–408, 1991.
[8] W. R. Hiatt, D. Nawaz, J. G. Regensteiner, and K. F. Hossack, “The evaluation of exercise performance in patients with peripheral vascular disease,” *Journal of Cardiopulmonary Rehabilitation and Prevention*, vol. 12, pp. 525–532, 1988.
[9] M. M. McDermott, P. Greenland, K. Liu et al., “Leg symptoms in peripheral arterial disease associated clinical characteristics and functional impairment,” *Journal of the American Medical Association*, vol. 286, no. 13, pp. 1599–1606, 2001.
[10] M. M. McDermott, K. Liu, P. Greenland et al., “Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms,” *Journal of the American Medical Association*, vol. 292, no. 4, pp. 453–461, 2004.
[11] M. M. McDermott, K. Liu, E. O’Brien et al., “Measuring physical activity in peripheral arterial disease: a comparison of two physical activity questionnaires with an accelerometer,” *Angiology*, vol. 51, no. 2, pp. 91–100, 2000.
[12] D. J. Sieminski and A. W. Gardner, “The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease,” *Vascular Medicine*, vol. 2, no. 4, pp. 286–291, 1997.
[13] J. E. Ware Jr., “The status of health assessment 1994,” *Annual Review of Public Health*, vol. 16, pp. 327–354, 1995.
[14] M. M. McDermott, J. M. Guralnik, L. Tian et al., “Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease,” *Journal of the American College of Cardiology*, vol. 50, no. 10, pp. 974–982, 2007.
[15] L. P. Fried and J. M. Guralnik, “Disability in older adults: evidence regarding significance, etiology, and risk,” *Journal of the American Geriatrics Society*, vol. 45, no. 1, pp. 92–100, 1997.
[16] A. Afaq, P. S. Montgomery, K. J. Scott, S. M. Blevins, T. L. Whitsett, and A. W. Gardner, “The effect of hypercholesterolemia on calf muscle hemoglobin oxygen saturation in patients with intermittent claudication,” *Angiology*, vol. 59, no. 5, pp. 534–541, 2008.
[17] A. W. Gardner and P. S. Montgomery, “The effect of metabolic syndrome components on exercise performance in patients with intermittent claudication,” *Journal of Vascular Surgery*, vol. 47, no. 6, pp. 1251–1258, 2008.
[18] P. S. Yusuf, S. Hawken, S. Öunpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” *The Lancet*, vol. 364, no. 9438, pp. 937–952, 2004.
[19] M. Simonsson, C. Schmidt, V. Sigurdadottir, M.-L. Helenius, and B. Fagerberg, “Life style habits such as alcohol consumption and physical activity in relation to serum apoB/apoA-I ratio amongst 64-year-old women with varying degrees of glucose tolerance,” *Journal of Internal Medicine*, vol. 262, no. 5, pp. 537–544, 2007.
[20] I. Holme, A. T. Høstmark, and S. A. Andersen, “ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study,” *Journal of Internal Medicine*, vol. 262, no. 2, pp. 235–243, 2007.
[21] A. W. Gardner, D. E. Parker, P. S. Montgomery, K. J. Scott, and S. M. Blevins, “Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial,” *Circulation*, vol. 123, no. 5, pp. 491–498, 2011.
[22] A. W. Gardner, P. S. Montgomery, K. J. Scott, A. Afaq, and S. M. Blevins, “Patterns of ambulatory activity in subjects with and without intermittent claudication,” *Journal of Vascular Surgery*, vol. 46, no. 6, pp. 1208–1214, 2007.
[23] P. Alaupovic, “Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins,” *Methods in Enzymology*, vol. 263, pp. 32–60, 1996.
[24] P. Alaupovic, “The concept of apolipoprotein-defined lipoprotein families and its clinical significance,” *Current Atherosclerosis Reports*, vol. 5, no. 6, pp. 459–467, 2003.
[25] W. J. McConathy, R. M. Greenhalgh, and P. Alaupovic, “Plasma lipid and apolipoprotein profiles of women with two types of peripheral arterial disease,” *Atherosclerosis*, vol. 50, no. 3, pp. 295–306, 1984.
A.W. Gardner, P.S. Montgomery, and D.E. Parker, “Metabolic syndrome impairs physical function, health-related quality of life, and peripheral circulation in patients with intermittent claudication,” *Journal of Vascular Surgery*, vol. 43, no. 6, pp. 1191–1196, 2006.

C. Behre, G. Bergström, and C. Schmidt, “Moderate physical activity is associated with lower ApoB/ApoA-I ratios independently of other risk factors in healthy, middle-aged men,” *Angiology*, vol. 61, no. 8, pp. 775–779, 2010.

M. Schilling, M. Ekner, W. Mlekusch et al., “Statin therapy improves cardiovascular outcome of patients with peripheral artery disease,” *European Heart Journal*, vol. 25, no. 9, pp. 742–748, 2004.

E. R. Mohler III, W. R. Hiatt, and M. A. Creager, “Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease,” *Circulation*, vol. 108, no. 12, pp. 1481–1486, 2003.

P. Alaupovic, T. Heinonen, L. Shurzinske, and D. M. Black, “Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels,” *Atherosclerosis*, vol. 133, no. 1, pp. 123–133, 1997.

R. Nael, P. S. Montgomery, K. J. Scott, S. M. Blevins, and A. W. Gardner, “Gender differences in the prevalence and management of metabolic syndrome and its components in patients with peripheral artery disease,” *Angiology*, vol. 62, no. 8, pp. 657–661, 2011.